Find a Doctor or Practice Location

Are you a referring physician?
I am searching for a
Reset Form
Daniel J. Landsburg, MD

Daniel J. Landsburg, MD Physician

Assistant Professor of Clinical Medicine

Dr. Landsburg is employed by Penn Medicine.

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Clinical Specialties


  • Hematology
  • Medical Oncology

Programs & Centers:

Board Certification:

  • Hematology, 2014
  • Internal Medicine, 2011
  • Medical Oncology, 2014

Clinical Expertise:

  • Bone Marrow Transplant
  • Cutaneous T-Cell Lymphoma
  • Lymphoma
  • Stem Cell Transplant

Description of Clinical Expertise

Non-Hodgkin lymphoma
Hodgkin lymphoma
Autologous stem cell transplantation

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: Temple University School of Medicine
Residency: Hospital of the University of Pennsylvania
Fellowship: Hospital of the University of Pennsylvania


American Society of Clinical Oncology, International American Society of Hematology, International

Hospital Affiliation

Dr. Landsburg is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.


Description of Research Expertise:

Double-hit B cell lymphoma
MYC-altered B cell lymphoma
Diffuse large B cell lymphoma
Aggressive B cell lymphoma

Selected Publications:

Rhodes Joanna, Landsburg Daniel J: Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma. Current hematologic malignancy reports : 2018.

Cherng Hua-Jay J, Sargent Rachel Lynn, Nasta Sunita Dwivedy, Svoboda Jakub, Schuster Stephen J, Mato Anthony R, Schrank-Hacker April, Morrissette Jennifer J D, Landsburg Daniel J: Interim PET/CT Result Is Not Predictive of Survival in Patients With MYC-rearranged Non-Burkitt Aggressive B-cell Lymphoma. Clinical lymphoma, myeloma & leukemia : 2018.

Landsburg Daniel J: Advancing the management of double hit lymphoma. Oncotarget 8 (45): 78245-78246,2017.

Winter Allison M, Landsburg Daniel J, Mato Anthony R, Isaac Krista, Hernandez-Ilizaliturri Francisco J, Reddy Nishitha, Smith Stephen, Shadman Mazyar, Smith Mitchell R, Caimi Paolo, Jagadeesh Deepa, Hill Brian T: A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib. Blood : 2017.

Landsburg Daniel J, Falkiewicz Marissa K, Maly Joseph, Blum Kristie A, Howlett Christina, Feldman Tatyana, Mato Anthony R, Hill Brian T, Li Shaoying, Medeiros L Jeffrey, Torka Pallawi, Hernandez-Ilizaliturri Francisco, Reddy Nishitha M, Singavi Arun, Fenske Timothy S, Chavez Julio C, Kaplan Jason B, Behdad Amir, Petrich Adam M, Bast Martin A, Vose Julie M, Olszewski Adam J, Costa Cristiana, Lansigan Frederick, Gerson James N, Barta Stefan K, Calzada Oscar, Cohen Jonathon B, Lue Jennifer K, Rivera Xavier: Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35 (20): JCO2017722157,2017.

Landsburg Daniel J, Falkiewicz Marissa K, Petrich Adam M, Chu Benjamin A, Behdad Amir, Li Shaoying, Medeiros L Jeffrey, Cassaday Ryan D, Reddy Nishitha M, Bast Martin A, Vose Julie M, Kruczek Kimberly R, Smith Scott E, Patel Priyank, Hernandez-Ilizaliturri Francisco, Karmali Reem, Rajguru Saurabh, Yang David T, Maly Joseph J, Blum Kristie A, Zhao Weiqiang, Vanslambrouck Charles, Nabhan Chadi: Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. British journal of haematology 175 (4): 631-640,2016.

Landsburg Daniel J: Management of Patients with MYC-Altered Lymphomas Current Hematologic Malignancy Reports 11 (3): 208-17,2016.

Landsburg Daniel J, Schuster Stephen J: Who Should Be Tested for Double-Hit Lymphoma? Journal of Oncology Practice/American Society of Clinical Oncology 12 (3): 243-4,2016.

Landsburg Daniel J, Petrich Adam M, Abramson Jeremy S, Sohani Aliyah R, Press Oliver, Cassaday Ryan, Chavez Julio C, Song Kevin, Zelenetz Andrew D, Gandhi Mitul, Shah Namrata, Fenske Timothy S, Jaso Jesse, Medeiros L Jeffrey, Yang David T, Nabhan Chadi: Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. Cancer 122 (4): 559-64,2015.

Howlett Christina, Snedecor Sonya J, Landsburg Daniel J, Svoboda Jakub, Chong Elise A, Schuster Stephen J, Nasta Sunita Dwivedy, Feldman Tatyana, Rago Allison, Walsh Kristy M, Weber Scott, Goy Andre, Mato Anthony: Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. British Journal of Haematology 170 (4): 504-14,2015.

Landsburg Daniel J, Nasta Sunita D, Svoboda Jakub, Morrissette Jennifer J D, Schuster Stephen J: 'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients. British Journal of Haematology 166 (3): 369-74,2014.

Academic Contact Info

Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-182
3400 Civic Center Boulevard

Philadelphia, PA 19104
Phone: (215) 615-7361
Patient appointments: 800-789-7366 (PENN)